CHPA on bar codes
This article was originally published in The Tan Sheet
Executive Summary
Use of the UPC code to address medication errors will "result in significant barriers in distribution channels" if it changes code's current intended use or efficiency, CHPA says in July 12 comments to FDA. Responding to agency's request for input on whether all OTC, Rx drugs should carry bar codes, trade association says it is unsure whether "a bar code in addition to the UPC on the package is either feasible or that institutions will have the appropriate tools to read this code and convert the information into a usable format that will reduce medication errors." CHPA cites need to establish "well-developed, evidence-based description" of medication errors involving OTC use in institutional settings. Group will make more detailed remarks at July 26 meeting (1"The Tan Sheet" June 24, 2002, p. 4)...
You may also be interested in...
FDA Drug Bar Code Proposal Could Extend To OTCs
FDA will seek comment on whether all OTC and Rx drugs should carry bar codes during a public meeting in Bethesda, Md. July 26
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.